Amarin Corporation plc (AMRN) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 6 wire items for AMRN, including 2 earnings updates, 2 press releases and news items and 2 SEC filings. The most recent was published Nov 9, 2026.
Financial highlights
Full financials- Revenue, TTM
- $176.11M
- Revenue growth
- -22.3%
- Net income, TTM
- -$19.14M
- Net margin
- -10.9%
- Cash
- $156.51M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks22+100%
2026-05-172026-11-08
Mix1090d
- Other5(50%)
- Earnings2(20%)
- SEC Filings2(20%)
- Analyst1(10%)
Activity · 52 weeks5933 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRAmarin Highlights New Data on Lipoprotein(a) and other Apolipoprotein B Containing Lipoproteins at American Heart Association (AHA) Scientific Sessions 2026DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted new clinical data evaluating lipoprotein(a) [Lp(a)] and other apolipoprotein B (apoB) containing lipoproteins as predictors of major adverse cardiovascular events (MACE), as well as new mechanistic findings examining the effects of eicosapentaenoic acid (EPA) on Lp(a) oxidation and related inflammatory and oxidative stress pathways. The data were presented at the American Heart Association (AHA) Scientific Sessions 2026 this weekend in Chicago, Illinois. The new research comes amid increase
- SECSEC Form 10-Q filed by Amarin Corporation plc10-Q - AMARIN CORP PLC\UK (0000897448) (Filer)
- SECSEC Form 8-K filed by Amarin Corporation plc8-K - AMARIN CORP PLC\UK (0000897448) (Filer)
- PRAmarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net IncomeDUBLIN and BRIDGEWATER, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the third quarter ended September 30, 2026 (Q3 2026) highlighting profitable third quarter results, strong momentum in its fully partnered international business strategy and continued U.S. market share leadership. Delivering On Our Performance Objectives"Our results in the third quarter demonstrate the continued positive trajectory in our operational, financial and strategic transformation, underscoring the progress we are making to strengthen our business, expand the
- PRAmarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)Pre-specified and Statistically Powered Key Endpoints Included Progression-free Survival (PFS) and Overall Survival (OS). Although Primary Endpoint of PFS Was Not Met, The Key Secondary Endpoint of OS Was Improved With VAZKEPA/VASCEPA Patients Taking VASCEPA Prior to and Following Liver Resection for CRCLM Were Estimated to Have an Approximately 32% Reduction in the Risk of Death at 5 Years Relative to the Control Arm DUBLIN and BRIDGEWATER, N.J., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today highlighted findings from the EPA for Metastasis Trial 2 (EMT2), a randomized,
- PRAmarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026DUBLIN and BRIDGEWATER, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report third quarter 2026 financial results and conduct a conference call on Wednesday, October 28, 2026. The Company will issue a press release detailing its third quarter 2026 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information on how to participate is as follows. Access to the live call:Via telephone: Dial in within the United States: 888-506-0062 International dial in: 973-528-0011Access Code: 314562 Via onlin
- PRAmarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA) 2026 ESC/European Renal Association (ERA) Cardiovascular and Chronic Kidney Disease Guideline Further Reinforces the Clinical Evidence Supporting Icosapent Ethyl DUBLIN and BRIDGEWATER, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today highlighted findings from multiple Amarin supported presentations at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. The research prese
- PRNew REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent PatientsDUBLIN and BRIDGEWATER, N.J., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted a new post hoc analysis from the landmark REDUCE-IT® cardiovascular outcomes trial, presented at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. The analysis showed that highly adherent participants who remained on icosapent ethyl (IPE) treatment for at least 1.5 years experienced approximately 30% relative risk reduction in major adverse cardiovascular events. Additionally, secondary prevention participants who stopped IPE treatment prematurely after a mean of 2.3
- PRNew Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026DUBLIN and BRIDGEWATER, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2026, August 28th - 31st, in Munich, Germany. The accepted abstracts add to the body of evidence generated from REDUCE-IT and related research investigating cardiovascular risk factors, biomarkers and potential mechanisms associated with the effects of icosapent ethyl or eicosapentaenoic acid (EPA). The presentations include analyses of treatment adherence, long-term outcomes, lipoprotein(a) [Lp(a)], coagulation bioma
- ANALYSTAnalyst resumed coverage on Amarin with a new price targetAnalyst resumed coverage of Amarin with a rating of Underweight and set a new price target of $13.00
- INSIDERSVP, CFO Fishman Peter L. converted options into 313 units of American Depositary Share and covered exercise/tax liability with 155 units of American Depositary Share, increasing direct ownership by 2% to 7,619 units (SEC Form 4)4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- SECSEC Form 10-Q filed by Amarin Corporation plc10-Q - AMARIN CORP PLC\UK (0000897448) (Filer)
- SECAmarin Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition8-K - AMARIN CORP PLC\UK (0000897448) (Filer)
- PRAmarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market PresenceQ2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA’s U.S. Market Share, an Improved OPEX Profile, and Positive Cash Flow Generation DUBLIN, Ireland and BRIDGEWATER, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the second quarter ended June 30, 2026 (Q2 2026) and highlighted positive outlooks associated with the one-year anniversary of its fully partnered international commercial strategy.
- INSIDEREVP, Chief Scientific Officer Ketchum Steven B converted options into 3,688 units of American Depositary Shares and covered exercise/tax liability with 1,887 units of American Depositary Shares, increasing direct ownership by 4% to 42,680 units (SEC Form 4)4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- INSIDEREVP, Chief Operating Officer Keenan David Paul converted options into 3,688 units of American Depositary Shares and covered exercise/tax liability with 1,926 units of American Depositary Shares, increasing direct ownership by 15% to 13,470 units (SEC Form 4)4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- INSIDERSVP, CFO Fishman Peter L. converted options into 2,447 units of American Depositary Shares and covered exercise/tax liability with 1,206 units of American Depositary Shares, increasing direct ownership by 20% to 7,461 units (SEC Form 4)4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- INSIDEREVP, Chief Legal Officer Provoost Jonathan converted options into 3,688 units of American Depositary Shares and covered exercise/tax liability with 1,264 units of American Depositary Shares, increasing direct ownership by 110% to 4,624 units (SEC Form 4)4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- PRAmarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026DUBLIN, Ireland and BRIDGEWATER, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report second quarter 2026 financial results and conduct a conference call on Wednesday, July 29, 2026. The Company will issue a press release detailing its second quarter 2026 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information on how to participate is as follows. Access to the live call:Via telephone: Dial in within the United States: 888-506-0062 International dial in: 973-528-0011Access Code: 444188 V
- INSIDERPresident and CEO Berg Aaron converted options into 6,250 units of American Depositary Shares and covered exercise/tax liability with 3,197 units of American Depositary Shares, increasing direct ownership by 4% to 85,648 units (SEC Form 4)4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- PRAmarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment LandscapeDUBLIN, Ireland and BRIDGEWATER, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, applauds the recent FDA approval of injectable apolipoprotein C-III (APOC3) therapies for the treatment of severe hypertriglyceridemia (sHTG), defined as triglycerides (TG) greater than or equal to 500 mg/dL.i These injectable therapies represent meaningful progress for patients at high risk for serious, sometimes life-threatening diseases associated with sHTG, including acute pancreatitis. "The renewed attention triglycerides generated by the introduction of innovative therapies is welcome, as they
- PRNew REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with HypertriglyceridemiaDUBLIN and BRIDGEWATER, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) (Amarin), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced new data from a post hoc analysis of the REDUCE-IT® trial presented at the European Atherosclerosis Society (EAS) Congress 2026 in Athens, Greece. The analysis, conducted in the REDUCE-IT placebo arm, evaluated risk-weighted apolipoprotein B (RW-apoB), an integrated metric designed to reflect the relative atherogenicity of apoB-containing lipoproteins. Among statin-treated patients with elevated triglycerides (TG) , RW-apoB was found to more effectively identify individuals at i
- SECAmarin Corporation plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - AMARIN CORP PLC\UK (0000897448) (Filer)
- SECSEC Form 10-Q filed by Amarin Corporation plc10-Q - AMARIN CORP PLC\UK (0000897448) (Filer)
- SECAmarin Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition8-K - AMARIN CORP PLC\UK (0000897448) (Filer)
AMRN FAQ
10 questionsWhat does Amarin Corporation plc do?
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the...What is the latest news on AMRN?
In the last 30 days Quantisnow tracked 6 wire items for AMRN: 2 earnings updates, 2 press releases and news items and 2 SEC filings. The most recent was published on November 9, 2026.What is AMRN revenue?
Amarin Corporation plc (AMRN) reported $176.11M of revenue for the twelve months ended Sep 30, 2026. That is down 22.3% from the year before. Revenue for fiscal 2025 was $213.65M.Is AMRN profitable?
No. Amarin Corporation plc reported a net loss of $19.14M for the twelve months ended Sep 30, 2026.How much cash and debt does AMRN have?
Amarin Corporation plc reported $156.51M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does AMRN stock trade?
Amarin Corporation plc (AMRN) is listed on NASDAQ.What sector and industry is AMRN in?
Amarin Corporation plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about AMRN?
Across the last 8 analyst actions on Amarin Corporation plc, there was 1 upgrade and 5 downgrades. The most recent action was from Analyst: Underweight with a $13.00 price target on 2026-08-21.What companies are similar to AMRN?
Notable peers in the same industry include MRK (Merck & Company Inc.), ARWR (Arrowhead Pharmaceuticals Inc.), IONS (Ionis Pharmaceuticals Inc.), NVS (Novartis AG). Compare AMRN side-by-side with any of them on Quantisnow.How can I track AMRN on Quantisnow?
Quantisnow aggregates Amarin Corporation plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AMRN to receive live email and push alerts on every new disclosure.